Uncategorized

Celon Pharma na  Kongresie ECNP (European College of Neuropsychopharmacology). W trakcie konferencji zostaną zaprezentowane wyniki badań przedklinicznych inhibitora PDE10a w obszarze dyskinez polewodopowych. Sesję posterową poprowadzi dr Mikołaj Matłoka, a tytuł posteru to:  “CPL500036 – a novel inhibitor of phosphodiesterase 10A – attenuates the development of L-DOPA-induced dyskinesias in 6-OHDA lesioned rats.” Prezentacja odbędzie się we wtorek 18 października 13:00Read more »

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: May 25, 2021, 5:26 PM Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) informs that on May 25, 2022 it adopted a resolution on recommendation for the Ordinary General Meeting of the Company onRead more »

The meeting of Polish pharmaceutical companies with representatives of Chineese

Celon Pharma S.A. was presented with the “Bulls and Bears” (“Byki i Niedźwiedzie”) award in the category “Debut of the year” – the oldest and most important award given to listed companies. The stock debut was one of the most important events of last year for us. We feel honoured that the jury of BullsRead more »

Once again the company was recognised in the prestigious ranking which lists the most dynamically developing enterprises in Poland. This year’s Forbes Diamonds list includes close to 2 400 companies. Celon Pharma S.A. took tenth place in the medium-sized company category in the Mazowieckie voivodeship and took fortieth place in the nationwide ranking. The rankingRead more »

The company received a nomination in the “Debut of the year” category and is up for the “Bull and Bear” award. “Bulls and Bears” are awarded annually by the Polish Stock Exchange “Parkiet” Newspaper to listed companies, as well as capital market institutions and organisers. The awards aim at promoting institutions and professionals who contributeRead more »